PET/CT vs MRI in Oncology: What Providers Should Know

In oncology, imaging is central to accurate diagnosis, treatment planning, and ongoing monitoring. Two of the most powerful modalities, PET/CT and MRI, often overlap in use, but they serve very different purposes. For providers, the challenge is deciding when one modality is the better choice, how they complement each other, and how to balance cost with clinical value.

We work with cancer centers, hospitals, and outpatient practices to evaluate which imaging systems truly fit their oncology workflow. Here's a breakdown of what you need to know about PET/CT and MRI in oncology care.

PET/CT: Functional and Metabolic Imaging

PET/CT combines metabolic information from PET with the anatomical detail of CT. It's the modality of choice for many staging and restaging exams because it reveals not just where a tumor is, but how metabolically active it is. 

Where PET/CT shines in oncology:

• Detecting and staging cancers – Particularly effective for lung cancer, lymphoma, melanoma, colorectal cancer, and head and neck tumors

• Evaluating treatment response – Metabolic changes often appear before structural changes, allowing earlier assessment of therapy effectiveness

• Identifying recurrence – Can detect metabolically active disease in many cancer types when structural imaging shows only post-treatment changes

• Guiding radiation therapy planning – Precise tumor mapping helps define treatment fields

ROI consideration: PET/CT systems carry higher upfront and operating costs (typically $1.5M–$3M for new systems, $600K–$1.2M for refurbished), but their ability to deliver both structural and functional data in one exam makes them highly valuable in comprehensive oncology care. Reimbursement for PET/CT scans typically ranges from $1,000–$3,000 depending on the indication.

PrizMED Tip: One oncology center we worked with found that their PET/CT investment paid for itself within 24 months through a combination of avoiding unnecessary surgeries, earlier treatment adjustments, and improved patient throughput compared to sequential imaging approaches.

MRI: Superior Soft Tissue Contrast

MRI provides unparalleled soft tissue resolution, making it the preferred modality for many tumors that CT or PET cannot characterize as clearly.

Where MRI is the better choice:

• Brain and spinal tumors requiring high-resolution detail and precise anatomical definition

• Hepatocellular carcinoma and liver metastases – MRI offers superior sensitivity for detecting and characterizing liver lesions, particularly with hepatobiliary contrast agents

• Pelvic cancers (prostate, cervical, rectal), where soft tissue differentiation is critical for staging and surgical planning

• Lesion characterization – When PET/CT shows uptake, but additional anatomical detail is needed to guide biopsy or treatment decisions

• Pediatric oncology and repeat imaging – No ionizing radiation makes MRI ideal for younger patients and frequent monitoring

ROI consideration: While MRI scans can take longer and require more infrastructure, they are reimbursed for a wide range of oncology applications (typically $500–$2,500 per scan). For practices specializing in CNS, hepatobiliary, or pelvic cancers, MRI equipment is often the stronger long-term investment. Costs range from $400K–$900K for refurbished 1.5T systems to $1M–$2.5M for new 3.0T systems.

PrizMED Tip: A hepatobiliary oncology practice saw their MRI utilization increase 40% after adding a 3.0T system with liver-specific protocols. The enhanced diagnostic confidence reduced the need for confirmatory biopsies and improved surgical planning accuracy.

When Providers Use Both

In many oncology settings, PET/CT and MRI are not competing technologies, but complementary tools. For example:

• A PET/CT scan may identify a suspicious lesion with high metabolic uptake, while an MRI characterizes the lesion's margins, vascular involvement, and relationship to nearby structures

• PET/CT is often chosen for whole-body staging to identify distant metastases, while MRI is used for detailed local tumor evaluation and surgical planning

• In liver cancer, PET/CT helps identify extrahepatic disease, while MRI provides superior characterization of liver lesions

Providers who plan their imaging investments around this complementary approach often see the best outcomes for both patients and financial sustainability.

Cost and Workflow Considerations

When weighing PET/CT and MRI, administrators and providers should ask:

• 

  What cancer types make up the bulk of our patient volume? Match modality strengths to your case mix

• Do we need functional imaging, detailed soft tissue characterization, or both? Consider how each modality supports your treatment protocols

• What infrastructure do we already have? Room shielding, HVAC, electrical capacity, and staff expertise all factor into the total cost

• Could refurbished systems help us expand capabilities without exceeding budget? High-quality refurbished equipment often delivers 70–80% cost savings with comparable diagnostic performance

• What are our reimbursement patterns? Analyze your payer mix and typical scan volumes to project revenue

PrizMED Tip: Many practices find success starting with one modality, then adding the other as their oncology services expand. Planning for trade-ins or staged upgrades protects long-term ROI and allows you to scale with demand rather than overcommitting capital upfront.

Your Oncology Imaging Partner

PET/CT and MRI both play critical roles in oncology. PET/CT delivers unmatched insight into tumor metabolism and treatment response, while MRI provides superior soft tissue resolution for local evaluation. The best choice depends on your patient population, your workflow, and your budget.

Many successful oncology programs don't choose between these modalities; they strategically deploy both, starting with the one that matches their highest-volume cancer types and adding the complementary system as services expand. This phased approach controls capital costs while building comprehensive imaging capabilities.

We've helped cancer centers nationwide build imaging programs that deliver both clinical excellence and strong financial returns. Whether you're launching an oncology program, upgrading existing equipment, or planning a multi-modality expansion, let's find the right imaging solution for your practice. With the right partner and a clear implementation strategy, your imaging investment will support better patient outcomes and strengthen your program's long-term viability.